Lactium, also known as casein decapeptide (αs1-casein hydrolysate), is a bioactive peptide derived from milk protein. Its use for stress reduction is supported by several preclinical and clinical studies, though the body of evidence is not robust and consists mainly of small-scale human trials and animal studies. The primary mechanism proposed is Lactium’s ability to bind to GABA_A receptors in the brain, which are associated with anxiolytic (anxiety-reducing) effects—similar to those of benzodiazepines, but reportedly without sedative or dependency risks.

Several randomized, placebo-controlled studies have evaluated Lactium in humans. For example, a 2006 study by Messaoudi et al. found that subjects experiencing stress showed significant reductions in cortisol and improvements in self-reported stress symptoms after supplementation with Lactium compared to placebo. Other trials have reported modest improvements in sleep quality and stress-related markers. However, these studies are often limited by small sample sizes, short durations, and potential conflicts of interest due to funding by product manufacturers.

Overall, while there is scientific rationale and some clinical evidence supporting Lactium’s use for stress management, the strength of the evidence is moderate at best and does not yet meet the standards for strong scientific consensus. Larger, independent studies are needed to fully validate its efficacy and safety for this purpose.